Keyword: AstraZeneca

Chugai Pharmaceuticals is shelling out ¥127.3 billion on a new R&D site in Yokohama, where it will combine the work of two research labs in nearby cities.

Yale researchers discovered that AstraZeneca’s anti-VEGF cancer drug cediranib may boost the effectiveness of PARP inhibitors.

AZ nets exec to lead breast cancer R&D; Teva stars in price-fix plot, but attorneys general say others "willingly" joined; EUSA Pharma nabs new execs.

The R&D shake-up at AstraZeneca continues as it hires cancer researcher Dr. Sunil Verma to run its breast cancer work.

Shares in FibroGen plummeted as the wording of its number-free statement raised concerns about the safety of the kidney disease drug.

Eisai installs new Alzheimer's clinical leadership team; Insys founder found guilty in landmark opioid suit; and Gilead's chief plots Kite CEO hire.

The results tee AstraZeneca and Daiichi Sankyo up to file for FDA approval in the first half of the fiscal year.

Viela's inebilizumab reduced attacks from the rare autoimmune disease neuromyelitis optica spectrum disorders by 73%.

Mohammed Dar lines up as the latest AstraZeneca/MedImmune executive to jump ship into U.K. biotech Immunocore.